Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as Colony Stimulating Factor 2 (granulocyte-macrophage), is a cytokine originally identified for its role in promoting the ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has introduced the aPAP ClearPath Dried Blood Spot (DBS) Test in the United States ...

Recombinant granulocyte-CSF (G-CSF) and granulocyte–macrophage-CSF (GM-CSF) have now been used to increase dangerously low white blood cell levels in many millions of cancer patients following ...

Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor, GM-CSF, in patients with ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...